Investigators working on Novartis’ personalized CTL019 CAR-T program at the University of Pennsylvania say that 90% of a small group of children suffering from very advanced cases of treatment-resistant acute lymphoblastic leukemia achieved complete remission after being treated in the newly updated trial.

…read more

Source: Penn-Novartis team ‘amazed’ at remissions, durable responses in leukemia CAR-T study


0 No comments